Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may unlock targeted cancer drug for more patients

NCT ID NCT06129084

Diagnosis Sponsor: Bernie Eigl Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a blood test can detect certain genetic changes (FGFR mutations) in patients with advanced bladder cancer better than the standard tissue biopsy. Currently, only patients with these mutations found in tumor tissue can get the drug erdafitinib. The blood test might catch mutations that tissue misses, potentially making more patients eligible for this targeted therapy. The study involves 260 participants and compares results from blood and tissue samples.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
blood test (ctDNA testing for FGFR mutations)
What this could lead to
If successful, this blood test could identify more patients with bladder cancer who might benefit from the targeted drug erdafitinib, improving treatment access.
What could go wrong
This is a diagnostic study, not a treatment trial. The blood test may not prove more accurate than tissue testing, and even if it is, it does not guarantee better outcomes for patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

260 people

The number who actually took part.

Started

Jan 2021

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with metastatic urothelial cancer who are screened for erdafitinib eligibility as standard of care.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with metastatic bladder cancer who are about to undergo tissue testing for FGFR mutations and who have blood samples drawn during the management of their disease are eligible to be included in this analysis. Exclusion Criteria: * Metastatic bladder cancer patients who will not have tissue sent for FGFR testing will be excluded from this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic bladder cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

stage IVb bladder cancer transitional cell carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic bladder cancer Metastatic urothelial carcinoma

Contacts and locations

Locations

  • Arthur J.E Child Comprehensive Cancer Centre

    Calgary, Alberta, T2N 5G2, Canada

  • BC Cancer Agency

    Vancouver, British Columbia, V5Z 4E6, Canada

  • CHU de Québec-Université Laval

    Québec, Quebec, G1R 2J6, Canada

  • Cross Cancer Institute

    Edmonton, Alberta, T6G 1Z2, Canada

  • London Health Sciences Centre

    London, Ontario, N6A 5W9, Canada

  • Ottawa Hospital Research Institute

    Ottawa, Ontario, K1H 8L6, Canada

  • Princess Margaret Cancer Centre

    Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.